Literature DB >> 18953180

Predictors of Plasmodium vivax malaria-induced nephropathy in young Korean men.

Byung Ha Chung1, Sei Won Lee, Sang Eun Lee, Tae Jun Hwang, Ho Sik Shin.   

Abstract

BACKGROUND: Plasmodium vivax malaria accounts for more than half of all malaria cases in Asia and Latin America. Despite the high prevalence of disease caused by this parasite, research into its effects (especially its renal effect) has lagged disproportionately. To investigate predictors of vivax malaria-induced nephropathy, we analyzed the cases of vivax malaria-induced nephropathy in young Korean men.
METHODS: This was a retrospective analysis of P. vivax patients with acute nephropathy (all males, n = 75), defined by an absolute increase in serum creatinine of 0.3 mg/dl or more (equal to an estimated glomerular filtration rate (eGFR) <80 ml/min) (group 1, n = 31) or proteinuria (group 2, n = 44), between January 2004 and December 2007. The eGFR was calculated using a simplified Modification of Renal Disease (MDRD) equation. None of the patients had a history of traveling abroad, drug abuse or blood transfusion. The clinical manifestations, laboratory abnormalities and predictors of nephropathy were reviewed.
RESULTS: Out of 398 cases of vivax malaria, 75 patients (all males) suffered from to vivax malaria-induced acute nephropathy. The mean age of the patients who were divided into two groups was 22.8 +/- 3.7 and 21.6 +/- 1.8 years, respectively (p = 0.089). In group 1, the total serum bilirubin significantly correlated with serum creatinine and eGFR (p = 0.004 and 0.035, correlation coefficient = 0.508 and -0.387, respectively). In group 2, 24-hour proteinuria significantly correlated with hemoglobin (p = 0.004, correlation coefficient = -0.424).
CONCLUSION: Total serum bilirubin (group 1, an absolute increase in serum creatinine of 0.3 mg/dl or more (equal to an eGFR <80 ml/min)) and hemoglobin (group 2, proteinuria) are useful to predict vivax-induced nephropathy. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18953180     DOI: 10.1159/000167023

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  6 in total

1.  Renal cortical necrosis and acute kidney injury associated with Plasmodium vivax: a neglected human malaria parasite.

Authors:  Vivek B Kute; Aruna V Vanikar; Pramod P Ghuge; Jitendra G Goswami; Mohan P Patel; Himanshu V Patel; Manoj R Gumber; Pankaj R Shah; Hargovind L Trivedi
Journal:  Parasitol Res       Date:  2012-06-06       Impact factor: 2.289

2.  An unusual case of Plasmodium vivax malaria monoinfection associated with crescentic glomerulonephritis: a need for vigilance.

Authors:  Mohan P Patel; Vivek B Kute; Manoj R Gumber; Dinesh N Gera; Pankaj R Shah; Himanshu V Patel; Hargovind L Trivedi; Aruna V Vanikar
Journal:  Parasitol Res       Date:  2012-07-18       Impact factor: 2.289

3.  Postrenal transplant Plasmodium vivax malaria: neglected and not benign.

Authors:  Vivek B Kute; Aruna V Vanikar; Pankaj R Shah; Jigar D Shrimali; Manoj R Gumber; Himanshu V Patel; Pranjal R Modi; Hargovind L Trivedi
Journal:  Parasitol Res       Date:  2012-12-13       Impact factor: 2.289

4.  Plasmodium vivax malaria-associated acute kidney injury, India, 2010-2011.

Authors:  Vivek B Kute; Hargovind L Trivedi; Aruna V Vanikar; Pankaj R Shah; Manoj R Gumber; Himanshu V Patel; Jitendra G Goswami; Kamal V Kanodia
Journal:  Emerg Infect Dis       Date:  2012-05       Impact factor: 6.883

5.  Outcome and prognostic factors of malaria-associated acute kidney injury requiring hemodialysis: A single center experience.

Authors:  V B Kute; P R Shah; B C Munjappa; M R Gumber; H V Patel; S H Jain; D P Engineer; V V Sai Naresh; A V Vanikar; H L Trivedi
Journal:  Indian J Nephrol       Date:  2012-01

Review 6.  Plasmodium vivax Biology: Insights Provided by Genomics, Transcriptomics and Proteomics.

Authors:  Catarina Bourgard; Letusa Albrecht; Ana C A V Kayano; Per Sunnerhagen; Fabio T M Costa
Journal:  Front Cell Infect Microbiol       Date:  2018-02-08       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.